- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- October 2025
- 150 Pages
Global
From €5249EUR$5,950USD£4,597GBP
From €4323EUR$4,900USD£3,785GBP
- Report
- September 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- April 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- September 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,469GBP
- Report
- April 2025
- 182 Pages
Global
From €3970EUR$4,500USD£3,476GBP
- Report
- February 2025
- 183 Pages
Global
From €3970EUR$4,500USD£3,476GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,250USD£3,172GBP
- Report
- October 2025
- 160 Pages
Global
From €2962EUR$3,358USD£2,594GBP
€3485EUR$3,950USD£3,052GBP
- Report
- October 2022
- 270 Pages
Global
From €2481EUR$2,813USD£2,173GBP
€3308EUR$3,750USD£2,897GBP
- Report
- January 2024
- 113 Pages
Global
From €3970EUR$4,500USD£3,476GBP
- Report
- August 2022
- 116 Pages
Global
From €3970EUR$4,500USD£3,476GBP
- Report
- September 2021
- 111 Pages
Global
From €3970EUR$4,500USD£3,476GBP
- Report
- July 2024
- 231 Pages
Global
From €5611EUR$6,360USD£4,913GBP
€7014EUR$7,950USD£6,142GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €2647EUR$3,000USD£2,318GBP
€3308EUR$3,750USD£2,897GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1941EUR$2,200USD£1,700GBP
€2426EUR$2,750USD£2,124GBP
- Report
- February 2022
- 210 Pages
Global
From €5294EUR$6,000USD£4,635GBP
€6617EUR$7,500USD£5,794GBP

Enbrel is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein composed of the extracellular ligand-binding portion of the human 75 kDa tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Enbrel works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation.
Enbrel is a widely used drug in the immune disorder drug market. It is approved for use in adults and children over the age of four. It is administered as a subcutaneous injection and is available in both prefilled syringes and autoinjectors.
The Enbrel market is highly competitive, with several companies offering similar products. These include Amgen, Pfizer, AbbVie, Janssen, and UCB. Show Less Read more